{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:29:06Z","timestamp":1769502546431,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Biostatistics and Bioinformatics Shared Resource of the University of Kentucky Markey Cancer Center","award":["P30 CA177558"],"award-info":[{"award-number":["P30 CA177558"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11060-021-03891-8","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T20:47:22Z","timestamp":1637786842000},"page":"153-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hematological adverse events in the management of glioblastoma"],"prefix":"10.1007","volume":"156","author":[{"given":"Catherine R.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zin W.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rani","family":"Jayswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison R.","family":"Butts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-0093","authenticated-orcid":false,"given":"John L.","family":"Villano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"3891_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"3891_CR2","first-page":"37","volume":"6","author":"EV Dressler","year":"2019","unstructured":"Dressler EV, Liu M, Garcia CR et al (2019) Patterns and disparities of care in glioblastoma. Neurooncol Pract 6:37\u201346","journal-title":"Neurooncol Pract"},{"key":"3891_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11060-019-03218-8","volume":"144","author":"CR Garcia","year":"2019","unstructured":"Garcia CR, Slone SA, Dolecek TA et al (2019) Primary central nervous system tumor treatment and survival in the United States, 2004\u20132015. J Neurooncol 144:179\u2013191","journal-title":"J Neurooncol"},{"key":"3891_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00280-011-1679-8","volume":"69","author":"JL Villano","year":"2012","unstructured":"Villano JL, Letarte N, Yu JM et al (2012) Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol 69:107\u2013113","journal-title":"Cancer Chemother Pharmacol"},{"key":"3891_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1215\/15228517-2006-024","volume":"9","author":"DE Gerber","year":"2007","unstructured":"Gerber DE, Grossman SA, Zeltzman M et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47\u201352","journal-title":"Neuro Oncol"},{"key":"3891_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1215\/15228517-2008-120","volume":"11","author":"TS Armstrong","year":"2009","unstructured":"Armstrong TS, Cao Y, Scheurer ME et al (2009) Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 11:825\u2013832","journal-title":"Neuro Oncol"},{"key":"3891_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/CMR.0b013e32832ccd58","volume":"21","author":"A Sabharwal","year":"2011","unstructured":"Sabharwal A, Waters R, Danson S et al (2011) Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res 21:502\u2013508","journal-title":"Melanoma Res"},{"key":"3891_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.amjmed.2012.04.026","volume":"125","author":"M Dior","year":"2012","unstructured":"Dior M, Coriat R, Mir O et al (2012) A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. Am J Med 125:828\u2013830","journal-title":"Am J Med"},{"key":"3891_CR9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ejca.2011.03.005","volume":"47","author":"FA Schutz","year":"2011","unstructured":"Schutz FA, Jardim DL, Je Y et al (2011) Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer 47:1161\u20131174","journal-title":"Eur J Cancer"},{"key":"3891_CR10","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085\u20134091","journal-title":"J Clin Oncol"},{"key":"3891_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708","journal-title":"N Engl J Med"},{"key":"3891_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","volume":"20","author":"R Stupp","year":"2002","unstructured":"Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375\u20131382","journal-title":"J Clin Oncol"},{"key":"3891_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"3891_CR14","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163\u2013170","journal-title":"Cancer Chemother Rep"},{"key":"3891_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-019-03167-2","volume":"143","author":"WJ Kim","year":"2019","unstructured":"Kim WJ, Dho YS, Ock CY et al (2019) Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. J Neurooncol 143:321\u2013328","journal-title":"J Neurooncol"},{"key":"3891_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11060-017-2580-z","volume":"135","author":"JL Campian","year":"2017","unstructured":"Campian JL, Piotrowski AF, Ye X et al (2017) Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. J Neurooncol 135:343\u2013351","journal-title":"J Neurooncol"},{"key":"3891_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/COC.0b013e3182a790ea","volume":"38","author":"G Lombardi","year":"2015","unstructured":"Lombardi G, Rumiato E, Bertorelle R et al (2015) Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am J Clin Oncol 38:514\u2013519","journal-title":"Am J Clin Oncol"},{"key":"3891_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/CAD.0b013e328356f5b0","volume":"23","author":"S Dixit","year":"2012","unstructured":"Dixit S, Baker L, Walmsley V et al (2012) Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 23:1099\u20131106","journal-title":"Anticancer Drugs"},{"key":"3891_CR19","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood.V88.5.1649.1649","volume":"88","author":"SL Gerson","year":"1996","unstructured":"Gerson SL, Phillips W, Kastan M et al (1996) Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 88:1649\u20131655","journal-title":"Blood"},{"issue":"6","key":"3891_CR20","doi-asserted-by":"publisher","first-page":"e228803","DOI":"10.1136\/bcr-2018-228803","volume":"12","author":"F Batalini","year":"2019","unstructured":"Batalini F, Kaufmann MR, Aleixo GF et al (2019) Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. BMJ Case Rep 12(6):e228803","journal-title":"BMJ Case Rep"},{"key":"3891_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-215797","author":"K Vandraas","year":"2016","unstructured":"Vandraas K, Tjonnfjord GE, Johannesen TB et al (2016) Persistent bone marrow depression following short-term treatment with temozolomide. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2016-215797","journal-title":"BMJ Case Rep"},{"key":"3891_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/cns-2015-0009","volume":"5","author":"AG Murphy","year":"2016","unstructured":"Murphy AG, Grossman SA (2016) Acute hemolysis in a patient with a newly diagnosed glioblastoma. CNS Oncol 5:125\u2013129","journal-title":"CNS Oncol"},{"key":"3891_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/1078155214524085","volume":"21","author":"JA Lewis","year":"2015","unstructured":"Lewis JA, Petty WJ, Harmon M et al (2015) Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. J Oncol Pharm Pract 21:220\u2013223","journal-title":"J Oncol Pharm Pract"},{"key":"3891_CR24","unstructured":"FDA. Temozolomide (marketed as Temodar): Aplastic Anemia. In: Consumer Update. Fall, 2007. Accessed Feb 2018"},{"key":"3891_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3171\/2016.7.JNS16609","volume":"127","author":"EJ Vaios","year":"2017","unstructured":"Vaios EJ, Nahed BV, Muzikansky A et al (2017) Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. J Neurosurg 127:132\u2013138","journal-title":"J Neurosurg"},{"key":"3891_CR26","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00432-012-1243-x","volume":"138","author":"M Williams","year":"2012","unstructured":"Williams M, Liu ZW, Woolf D et al (2012) Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. J Cancer Res Clin Oncol 138:1683\u20131688","journal-title":"J Cancer Res Clin Oncol"},{"key":"3891_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10143-017-0903-3","volume":"41","author":"T Saito","year":"2018","unstructured":"Saito T, Sugiyama K, Hama S et al (2018) Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. Neurosurg Rev 41:621\u2013628","journal-title":"Neurosurg Rev"},{"key":"3891_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14740330902918281","volume":"8","author":"VA Trinh","year":"2009","unstructured":"Trinh VA, Patel SP, Hwu WJ (2009) The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8:493\u2013499","journal-title":"Expert Opin Drug Saf"},{"key":"3891_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","volume":"127","author":"JS Mendez","year":"2016","unstructured":"Mendez JS, Govindan A, Leong J et al (2016) Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol 127:329\u2013335","journal-title":"J Neurooncol"},{"key":"3891_CR30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.24951","volume":"116","author":"GY Ku","year":"2010","unstructured":"Ku GY, Yuan J, Page DB et al (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116:1767\u20131775","journal-title":"Cancer"},{"key":"3891_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.bjc.6602934","volume":"94","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Miyamoto M, Cho Y et al (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275\u2013280","journal-title":"Br J Cancer"},{"key":"3891_CR32","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-10-2557","volume":"17","author":"J Lohr","year":"2011","unstructured":"Lohr J, Ratliff T, Huppertz A et al (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 17:4296\u20134308","journal-title":"Clin Cancer Res"},{"key":"3891_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ygyno.2007.10.012","volume":"108","author":"RP Rocconi","year":"2008","unstructured":"Rocconi RP, Matthews KS, Kemper MK et al (2008) Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 108:336\u2013341","journal-title":"Gynecol Oncol"},{"key":"3891_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3892\/mco.2020.2150","volume":"13","author":"KG Ho","year":"2020","unstructured":"Ho KG, Uhlmann EN, Wong ET et al (2020) Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma. Mol Clin Oncol 13:80","journal-title":"Mol Clin Oncol"},{"key":"3891_CR35","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet P, Jackson C, Koyama S et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24:1459\u20131468","journal-title":"Nat Med"},{"key":"3891_CR36","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1200\/JCO.1995.13.7.1632","volume":"13","author":"PA Bunn Jr","year":"1995","unstructured":"Bunn PA Jr, Crowley J, Kelly K et al (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13:1632\u20131641","journal-title":"J Clin Oncol"},{"key":"3891_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0360-3016(01)01544-9","volume":"50","author":"S Staar","year":"2001","unstructured":"Staar S, Rudat V, Stuetzer H et al (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy\u2013results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161\u20131171","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3891_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-017-2668-5","volume":"136","author":"AJ Lin","year":"2018","unstructured":"Lin AJ, Campian JL, Hui C et al (2018) Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol 136:403\u2013411","journal-title":"J Neurooncol"},{"key":"3891_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-010-0843-8","volume":"19","author":"A Chan","year":"2011","unstructured":"Chan A, Fu WH, Shih V et al (2011) Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 19:497\u2013504","journal-title":"Support Care Cancer"},{"key":"3891_CR40","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00520-013-1768-9","volume":"21","author":"A Chan","year":"2013","unstructured":"Chan A, Lee CP, Chiang J et al (2013) Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. Support Care Cancer 21:2137\u20132143","journal-title":"Support Care Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03891-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T14:08:12Z","timestamp":1640700492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03891-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3891"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03891-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. Data was requested through the National Clinical Trials Network.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}